Chk1 activation attenuates sensitivity of lapatinib in HER2-positive gastric cancer

Area of Science:

• Molecular Biology
• Cancer Research
• Cell Signaling

Background:

• The ATM and Rad3-related (ATR)/checkpoint kinase 1 (Chk1) pathway is crucial for DNA damage response and homologous recombination.
• Chk1 phosphorylation is linked to resistance against chemotherapy and radiotherapy.

Purpose of the Study:

• To investigate the role of the ATR/Chk1 pathway in regulating lapatinib sensitivity in HER2-positive gastric cancer.
• To explore potential therapeutic strategies targeting this pathway.

Main Methods:

• Utilized two HER2-positive gastric cancer cell lines (NCI-N87 and MKN7).
• Administered lapatinib and assessed its effects on HER2, EGFR, and downstream signaling pathways.
• Manipulated Chk1 phosphorylation levels to evaluate impacts on lapatinib sensitivity.
• Analyzed cell cycle progression, proliferation, apoptosis, and DNA damage markers.

Main Results:

• Lapatinib inhibited phosphorylated HER2/EGFR and EGFR/HER2 complex formation in both cell lines.
• NCI-N87 cells showed higher lapatinib sensitivity with lapatinib-induced G1 arrest and reduced Chk1 phosphorylation.
• MKN7 cells exhibited increased Chk1 phosphorylation and resistance to lapatinib.
• Inhibition of Chk1 phosphorylation in MKN7 cells enhanced lapatinib sensitivity, increasing anti-proliferative effects and DNA damage.
• Conversely, increased Chk1 phosphorylation in NCI-N87 cells attenuated lapatinib's effects.

Conclusions:

• The ATR/Chk1 pathway significantly modulates lapatinib sensitivity in HER2-positive gastric cancer.
• Targeting Chk1 phosphorylation presents a promising strategy to overcome lapatinib resistance.
• This study elucidates a novel mechanism for enhancing lapatinib efficacy in gastric cancer treatment.